Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet’s Syndrome

Uveitis along with oral and genital ulcers characterize the main clinical features of Behçet’s syndrome (BS) [1]. BS-related uveitis significantly impacts patients’ quality of life in several domains, beyond the sole influence on visual acuity [2]. In accordance with the European Alliance of Associations for Rheumatology (EULAR) recommendations, BS patients with posterior segment involvement should be treated with conventional immunosuppressants or biologic response modifier agents. Those with an initial or recurrent episode of acute sight-threatening uveitis should receive high-dose corticosteroids (CS) and interferon-α or tumor necrosis factor (TNF)-α monoclonal antibodies [3], with the latter being increasingly recommended as first-line corticosteroid-sparing agents. Indeed, an expert panel from the American Uveitis Society reported substantial evidence in support of the use of anti-TNF therapies for several well-recognized forms of uveitis, and strongly recommended early administration of infliximab or adalimumab (ADA) in patients with vision-threatening ocular manifestations of BS [4]. In this regard, the use of monoclonal TNF-α antibodies has significantly improved visual prognosis in BS patients and widened therapeutic alternatives for the management of such a sight-threatening condition. Nevertheless, the development of several ADA biosimilars after the recent patent expiration of the original product has raised some concerns in the scientific community, especially on aspects such as immunogenicity, antidrug antibody formation, and safety and efficacy issues [5, 6]. Additionally, the demonstrated efficacy and safety profile of SB5 (Imraldi^®), an ADA biosimilar, in patients with rheumatoid arthritis may not guarantee extrapolation to other indications, since it is not a very sensitive model for the detection of potential differences between ADA biosimilars and the reference product [7]. Data regarding its efficacy in BS-related uveitis are scarce. We herein provide our experience on BS-related uveitis treated with SB5.

Eight patients (six male and two female) were enrolled in the study. Mean ± SD age at uveitis onset was 35.38 ± 6.89 years, mean disease duration was 14.75 ± 7.42 years, and mean treatment duration with SB5 was 16.38 ± 3.93 months. Demographic and clinical characteristics are displayed in Table 1. With regard to the anatomical pattern, uveitis was posterior in four eyes, whereas 12 eyes had panuveitis. Retinal vasculitis was encountered in two eyes affected by posterior uveitis and in two eyes with panuveitis. One eye also had uveitic macular edema at baseline (OCT central macular thickness 487 µm). SB5 was administered subcutaneously at the standard dose of 40 mg every 2 weeks. A posologic adjustment was performed in one patient (SB5 40 mg every 10 days) because of uncontrolled systemic disease, with remission of mucocutaneous lesions within a few weeks.

The number of ocular relapses during the 12 months prior to SB5 initiation and at the last follow-up visit was 8 (100 relapses/100 patients/year) and 0, respectively (p = 0.04). Over a mean follow-up of 16-months, complete resolution of inflammation was observed in all affected eyes. Concerning FA findings, retinal vasculitis resolved in four out of four eyes affected at baseline evaluation. A statistically significant decrease in retinal vasculitis occurrence was detected during the overall study period (p = 0.02). Post hoc analysis, however, did not reveal a significant difference between baseline and 3 months (p = 0.13) or between baseline and last follow-up visit (p = 0.13). Figure 1 shows the resolution of panuveitis and occlusive retinal vasculitis in a BS patient affected by bilateral ocular involvement. Median ± IQR BCVA expressed in logMAR at baseline and last follow-up visit was 0.00 ± 0.13 and 0.00 ± 0.05, respectively (p = 0.11). No new ocular complications emerged during SB5 therapy. Treatment with SB5 was well tolerated, and no adverse events were reported.

In the present case series, we have investigated the role of SB5, an ADA biosimilar, as a potential weapon for the treatment of BS-related uveitis. TNF-α blockade has revolutionized the treatment of BS-related uveitis by improving visual prognosis. In this context, our working group has highlighted through real-life data the effectiveness of TNF-α inhibitors ADA and infliximab for the long-term management of BS-related uveitis [10, 11]. High similarities between SB5 and its reference product have been reported in terms of biological characteristics and pharmacokinetic effects [12]. Nevertheless, biosimilars have raised some concerns with regard to their immunogenicity, safety profile, antidrug antibody formation and extrapolation to other indications from studies conducted in rheumatoid arthritis [5‐7]. To the best of our knowledge, the present case series represents the largest sample of BS patients affected by uveitis and successfully treated with SB5. Specifically, a significant reduction in uveitis relapses was observed, which is consistent with results obtained by treating BS-related uveitis with the ADA originator. Indeed, a significant decrease in the number of uveitis relapses from 200 per 100 patients/year to 8.5 per 100 patients/year was previously reported in patients treated with the reference product [11]. Additionally, the resolution of retinal vasculitis in four out of four eyes at 3 months and its maintenance during the study period further support the rapid and sustained efficacy of SB5 in treating intraocular inflammation in BS patients. Similar findings are described in a larger cohort of patients suffering from retinal vasculitis and treated with ADA originator [13]. The availability of rapid-acting biologic agents represents a key factor in the therapy of BS-related uveitis, given the high risk of developing long-term structural damage and irreversible visual loss, especially in patients carrying specific risk factors, such as male gender, early age at onset and uveitis duration [14]. In this context, most patients in our cohort were young men, and additionally, six out of eight were positive for HLA-B51, which may predict the development of long-term structural complications, alongside uveitis duration and the presence of panuveitis [15]. With regard to visual acuity, median BCVA did not change significantly between baseline and last follow-up visit. The lack of statistical differences may be explained by the high visual acuity at SB5 initiation and the early administration of biologic therapy. This may suggest the ability of SB5 to maintain visual acuity.

These findings should be interpreted with caution in the context of study limitations such as the small sample size and the lack of a prospective properly design protocol.

The SB5 biosimilar has been shown to be a valid option for effective management of BS-related uveitis. Indeed, SB5 efficacy was supported by its ability to dramatically reduce uveitis relapses, treat retinal vasculitis and preserve visual acuity.